Be Well Medical Center | Berkley, MI

Research site

(Unclaimed)

Location

1964 11 Mile Road, Berkley, Michigan, United States of America

Site insights

Top conditions

Top treatments

Emtricitabine

Lenacapavir

Tenofovir Alafenamide

Bictegravir

TDF

Tenofovir Disoproxil Fumarate

Rilpivirine

TAF

Ritonavir

Elvitegravir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 52 total trials

Locations recently updated

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS...

Enrolling

HIV-1-infection

Drug: Lenacapavir Injection

Drug: GS-3242 Injection

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting

HIV-1 Infection

Drug: Lenacapavir Injection

Drug: Lenacapavir Tablet

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: DOR/ISL

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Active, not recruiting

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: Placebo to DOR/ISL

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting

HIV-1 Infection

Drug: ISL/LEN FDC

Drug: B/F/TAF

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) (PURPOSE 365)

The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absor...

Active, not recruiting

HIV Pre-exposure Prophylaxis

Drug: Lenacapavir Tablet

Drug: Lenacapavir Injection

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PURPOSE 2)

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of a...

Active, not recruiting

Pre-Exposure Prophylaxis of HIV Infection

Drug: Sub-cutaneous (SC) Lenacapavir (LEN)

Drug: PTM Oral LEN

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvim...

Enrolling

HIV Infections

Drug: Cabotegravir

Drug: Teropavimab

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed (WONDERS1)

The goal of this clinical study is to learn more about the experimental drugs lepetegravir and lenacapavir pacfosacil; to compare the combination of...

Active, not recruiting

HIV-1-Infection

Drug: Lepetegravir

Drug: Lepetegravir/Lenacapavir pacfosacil FDC

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (ISLEND-1)

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regi...

Active, not recruiting

HIV-1-infection

Drug: B/F/TAF

Drug: PTM ISL/LEN

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (ISLEND-2)

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LE...

Active, not recruiting

HIV-1-Infection

Drug: Antiretroviral Combinations

Drug: ISL/LEN

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting

HIV-1-infection

Drug: Optimized Background Regimen (OBR)

Drug: Oral Lenacapavir Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms